A woman named Rachel Davies from Wales is facing a heartbreaking battle with secondary breast cancer. Despite knowing that a drug called Enhertu could prolong her life, she is unable to access it due to it not being funded on the NHS in Wales, England, and Northern Ireland. This drug has the potential to give patients with a specific type of incurable breast cancer an additional six months to live on average. NICE, the health assessment body, has rejected funding for Enhertu, citing its cost as a barrier. However, the drug is available in 19 European countries and Scotland.
Rachel is among approximately 1,000 individuals in a similar predicament, unable to access a potentially life-extending treatment due to lack of funding. Moving to Scotland, where the drug is available, has crossed Rachel’s mind, but the thought of being away from her family during such a challenging time is a significant obstacle. Private funding for the drug is also not feasible due to the high costs involved.
Diagnosed with breast cancer in 2021, Rachel underwent various treatments, including a mastectomy, chemotherapy, and radiotherapy. However, the cancer spread to her bones and lungs shortly after her treatment ended, leading to a secondary cancer diagnosis with limited treatment options. Rachel believes that Enhertu could potentially stop the cancer progression, offering her hope for more time with her family.
HER2-low breast cancer, the subtype Rachel is battling, has lower levels of the HER2 protein on cell surfaces. Drug companies and charities have criticised NICE’s decision not to fund Enhertu, highlighting the importance of access to multiple treatment options for individuals with secondary breast cancer. Breast Cancer Now’s chief executive describes the situation as “deeply unjust,” emphasising the significance of extending lives and providing hope through innovative treatments.
NICE’s recent changes in funding decisions have left Rachel feeling confused and frustrated, especially seeing other countries approve the drug while Wales, England, and Northern Ireland have not. Rachel’s sister Melanie has set up a fundraising campaign to support Rachel in obtaining the treatments she needs, aiming to create lasting memories with loved ones during this challenging time.
The Welsh Government relies on NICE’s recommendations to balance the costs and benefits of treatments available to patients in Wales. Despite efforts to secure funding by modifying the decision-making process, NICE ultimately deemed Enhertu as not cost-effective. This ordeal has shed light on the challenges faced by individuals seeking access to life-prolonging treatments despite their potential benefits.
Rachel’s story highlights the complexities and inequalities in accessing vital treatments for life-threatening conditions like cancer. As she continues her fight against breast cancer, her plea for more time and the hope that comes with innovative treatments resonates with many in similar situations.